A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...